The DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
Constitutively active androgen receptor splice variants expressed in castration-resistant prostate cancer require full-length androgen receptor.
Open accessAbstract
Androgen receptor (AR) splice variants lacking the ligand binding domain (ARVs), originally isolated from prostate cancer cell lines derived from a single patient, are detected in normal and malignant human prostate tissue, with the highest levels observed in late stage, castration-resistant prostate cancer. The most studied variant (called AR-V7 or AR3) activates AR reporter genes in the absence of ligand and therefore, could play a role in castration resistance. To explore the range of potential ARVs, we screened additional human and murine prostate cancer models using conventional and next generation sequencing technologies and detected several structurally diverse AR isoforms. Some, like AR-V7/AR3, display gain of function, whereas others have dominant interfering activity. We also find that ARV expression increases acutely in response to androgen withdrawal, is suppressed by testosterone, and in some models, is coupled to full-length AR (AR-FL) mRNA production. As expected, constitutively active, ligand-independent ARVs such as AR-V7/AR3 are sufficient to confer anchorage-independent (in vitro) and castration-resistant (in vivo) growth. Surprisingly, this growth is blocked by ligand binding domain-targeted antiandrogens, such as MDV3100, or by selective siRNA silencing of AR-FL, indicating that the growth-promoting effects of ARVs are mediated through AR-FL. These data indicate that the increase in ARV expression in castrate-resistant prostate cancer is an acute response to castration rather than clonal expansion of castration or antiandrogen-resistant cells expressing gain of function ARVs, and furthermore, they provide a strategy to overcome ARV function in the clinic.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The activity of these variants still depends on the presence of a full-length AR, although treatment with the AR antagonist MDV3100 or siRNA knockdown of full-length AR inhibited transcription and androgen-free growth (77).”
From Minireview: Alternative Activation Pathways for the Androgen Receptor in Prostate Cancer (2011) · cites this paper as [77]
In the citing paper
“Moreover, the constitutive activity attributed to some variants may still rely on the presence of the full-length AR to mediate binding of AR to DNA and stimulate transcription (77).”
From Minireview: Alternative Activation Pathways for the Androgen Receptor in Prostate Cancer (2011) · cites this paper as [77]
In the citing paper
“In one study, endogenous expression of variant mRNA in patient samples and xenografts is much lower (ϳ0.1-2.5%)relative to full-length AR mRNA (77).”
From Minireview: Alternative Activation Pathways for the Androgen Receptor in Prostate Cancer (2011) · cites this paper as [77]
In the citing paper
“Interestingly, comparison of the transcriptome of variants with that of full-length AR suggests a significant amount of target specificity for each variant (76 -78).”
From Minireview: Alternative Activation Pathways for the Androgen Receptor in Prostate Cancer (2011) · cites this paper as [77]
In the citing paper
“Two such variants, human AR-V7, identified in CR prostate cancer specimens, and mouse AR-V4, from the murine Myc-CaP cell line, demonstrate ligand-free activation of a 4xARE-Luc promoter as well as promoting CR LNCaP tumor growth.”
From Minireview: Alternative Activation Pathways for the Androgen Receptor in Prostate Cancer (2011) · cites this paper as [77]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
TopHat: discovering splice junctions with RNA-Seq
Trapnell, C., Pachter, L. S., & Salzberg, S. L. (2009) · Bioinformatics · doi:10.1093/bioinformatics/btp120 · Cited by 11,682
Development of a second-generation antiandrogen for treatment of advanced prostate cancer.
Tran, C., Ouk, S., Clegg, N. J., Chen, Y., Watson, P. A., Arora, V., Wongvipat, J., Smith-Jones, P. M., Yoo, D., Kwon, A., et al. (2009) · Science · doi:10.1126/science.1168175 · Cited by 2,292
Self-citationHu, R., Dunn, T. A., Wei, S., Isharwal, S., Veltri, R. W., Humphreys, E., Han, M., Partin, A. W., Vessella, R. L., Isaacs, W. B., et al. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-2764 · Cited by 1,077
Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1–2 study
Scher, H. I., Beer, T. M., Higano, C. S., Anand, A., Taplin, M., Efstathiou, E., Rathkopf, D. E., Shelkey, J., Yu, E. Y., Alumkal, J. J., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60172-9 · Cited by 1,063
Scher, H. I., & Sawyers, C. L. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.03.4777 · Cited by 1,025
Self-citationGuo, Z., Yang, X., Sun, F., Jiang, R., Linn, D. E., Chen, H., Chen, H., Kong, X., Melamed, J., Tepper, C. G., et al. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-3795 · Cited by 880
Dehm, S. M., Schmidt, L. J., Heemers, H. V., Vessella, R. L., & Tindall, D. J. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-0594 · Cited by 834
Sun, S., Sprenger, C. C. T., Vessella, R. L., Haugk, K., Soriano, K., Mostaghel, E. A., Page, S. T., Coleman, I. M., Nguyen, H. M., Sun, H., et al. (2010) · Journal of Clinical Investigation · doi:10.1172/jci41824 · Cited by 748
He, B., Kemppainen, J., & Wilson, E. M. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.m002807200 · Cited by 441
Molecular basis of androgen insensitivity
Brinkmann, A. O. (2001) · Molecular and Cellular Endocrinology · doi:10.1016/s0303-7207(01)00466-x · Cited by 345
Cited by
Sorted by citations
Items 501–600 of 643
The Role of Enzalutamide in the Treatment of Castration-Resistant Prostate Cancer
Rawlinson, A., Mohammed, A. A., Miller, M. A. W., & Kunkler, R. B. (2012) · Future Oncology · doi:10.2217/fon.12.99 · Cited by 4
Luo, Y., Li, Q., Yang, X., Wei, D., Feng, B., Li, M., Han, Y., Zhao, J., Lin, Y., Li, Q., et al. (2021) · Disease Markers · doi:10.1155/2021/6649579 · Cited by 4
The androgen receptor for the radiation oncologist
Quéro, L., Rozet, F., Beuzeboc, P., & Hennequin, C. (2015) · Cancer/Radiothérapie · doi:10.1016/j.canrad.2015.02.008 · Cited by 5
Kobayashi, M., Huang, Y., Jin, C., Luo, Y., Okamoto, T., Wang, F., & McKeehan, W. L. (2011) · The Prostate · doi:10.1002/pros.21386 · Cited by 4
Abiraterone in prostate cancer.
Ryan, C. J. (2010) · PubMed · Cited by 4
Nicholson, C., Vela, I., & Williams, E. D. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-804003-4.00003-7 · Cited by 4
Afonso, A., Silva, J., Lopes, A. R., Coelho, S., Patrão, A. S., Rosinha, A. O., Carneiro, F., Pinto, A. R., Maurício, M. J., & Medeiros, R. (2020) · Pharmacogenomics · doi:10.2217/pgs-2020-0008 · Cited by 4
Androgen Receptor Gene Rearrangements: New Perspectives on Prostate Cancer Progression
Brand, L. J., & Dehm, S. M. (2013) · Current Drug Targets · doi:10.2174/13894501113149990151 · Cited by 4
Evolution of the prostate cancer genome towards resistance
Lorenzin, F., & Demichelis, F. (2019) · Journal of Translational Genetics and Genomics · doi:10.20517/jtgg.2019.01 · Cited by 4
Re: AR-V7 and Resistance to Enzalutamide and Abiraterone in Prostate Cancer
Anand, A., & Bjartell, A. S. (2014) · European Urology · doi:10.1016/j.eururo.2014.11.020 · Cited by 4
Alterations in AR-FOXA1 signaling in prostate cancer progression and therapeutic resistance
Gao, S., Patten, N. D., & Cai, C. (2025) · Journal of the National Cancer Center · doi:10.1016/j.jncc.2025.05.003 · Cited by 4
Wang, H., Gao, A. C., Xia, R., Wu, C., Hsu, S., Chen, C., & Shih, T. (2025) · Cancers · doi:10.3390/cancers17030351 · Cited by 3
Yu, K., Ji, L., Bu, F., Liu, Z., Wang, L., Jian, T., Chen, S., & Liang, X. (2023) · Journal of Men s Health · doi:10.22514/jomh.2023.057 · Cited by 4
Pérez, P. A., Silva, T. Y., Toledo, J., Gomá, L., Paul, A. L. D., Quintar, A. A., & Gutiérrez, S. (2025) · Chemosphere · doi:10.1016/j.chemosphere.2025.144145 · Cited by 3
Urolithins: Emerging natural compound targeting castration-resistant prostate cancer (CRPC)
Navin, A. K., Rejani, C. T., Chandrasekaran, B., & Tyagi, A. (2025) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2025.118058 · Cited by 4
Truncated Androgen Receptor Splice Variants in Prostate Cancer
Lonergan, P. E., & Tindall, D. J. (2013) · Springer eBooks · doi:10.1007/978-1-4614-6828-8_13 · Cited by 3
New insight into mechanisms of castration resistance
Payton, S. (2010) · Nature Reviews Urology · doi:10.1038/nrurol.2010.171 · Cited by 3
Androgen Receptor in Health and Disease
Marcelli, M. (2017) · Springer eBooks · doi:10.1007/978-3-319-46086-4_2 · Cited by 3
Hamid, A. R. A. H., Velez, M. V. L., Dudek, A. M., Jansen, C. F. J., Smit, F. P., Aalders, T. W., Verhaegh, G. W. C. T., Schaafsma, E., Sedelaar, J. P. M., & Schalken, J. A. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.721659 · Cited by 3
Treatment Sequencing in Metastatic Castration-Resistant Prostate Cancer: A Clinical Commentary
Stein, C. A. (2015) · Clinical Genitourinary Cancer · doi:10.1016/j.clgc.2015.05.005 · Cited by 3
The role of abiraterone in the management of metastatic castration-resistant prostate cancer
Rawlinson, A., Mohammed, A. A., Beatty, J. D., Bell, R., & Miller, M. A. W. (2012) · Expert Review of Anticancer Therapy · doi:10.1586/era.12.12 · Cited by 3
Martin, S. K., Fiandalo, M. V., & Kyprianou, N. (2013) · Springer eBooks · doi:10.1007/978-1-4614-6182-1_15 · Cited by 3
Advances in genetics: widening our understanding of prostate cancer
Pine, A. C., Fioretti, F. M., Brooke, G. N., & Bevan, C. L. (2016) · F1000Research · doi:10.12688/f1000research.8019.1 · Cited by 3
Paliouras, M., Alvarado, C., & Trifiro, M. A. (2016) · InTech eBooks · doi:10.5772/64392 · Cited by 3
Androgen Receptor Splice Variants Are Not Substrates of Nonsense‐Mediated Decay
Ajiboye, A. S., Esopi, D., Yegnasubramanian, S., & Denmeade, S. R. (2017) · The Prostate · doi:10.1002/pros.23323 · Cited by 3
Ji, H., Li, Y., Liu, Z., Tang, M. M., Zou, L., Su, F., Zhang, Y., Zhang, J., Li, H., Li, L., et al. (2020) · Frontiers in Endocrinology · doi:10.3389/fendo.2020.00167 · Cited by 3
Androgen-Sensitized Apoptosis of HPr-1AR Human Prostate Epithelial Cells
Chen, C., Dienhart, J. A., & Bolton, E. C. (2016) · PLoS ONE · doi:10.1371/journal.pone.0156145 · Cited by 2
Büchler, T., Bobek, V., & Kološtová, K. (2018) · Klinicka onkologie · doi:10.14735/amko20189 · Cited by 2
Valente-Santos, J., Vitorino, R. M. P., Sousa-Mendes, C., Oliveira, P. A., Colaço, B., Faustino‐Rocha, A. I., Neuparth, M. J., Leite-Moreira, A. F., Duarte, J. A., Ferreira, R. M., et al. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms25010550 · Cited by 2
Genetic and epigenetic alterations in human cancers
Gerashchenko, G. V., Kashuba, V. I., & Tukalo, M. A. (2024) · Biopolymers and Cell · doi:10.7124/bc.000aaa · Cited by 2
Thelen, P., Taubert, H. W., Duensing, S. M., Kristiansen, G., Merseburger, A. S., & Cronauer, M. V. (2018) · Aktuelle Urologie · doi:10.1055/s-0043-115426 · Cited by 2
The Role of Androgen Receptor in Prostate Cancer
Berger, A., & Rickman, D. S. (2017) · Molecular pathology library · doi:10.1007/978-3-319-64096-9_20 · Cited by 2
Second-Line Hormonal for Castrate-Resistant Prostate Cancer
Parihar, J. S., & Kim, I. Y. (2015) · Elsevier eBooks · doi:10.1016/b978-0-12-800077-9.00057-8 · Cited by 2
Oxidative Stress and Castration-Resistant Prostate Cancer
Shiota, M. (2018) · Springer eBooks · doi:10.1007/978-981-10-7013-6_21 · Cited by 2
Fusion transcripts: hopes and pitfalls in tranquilizing the trouble mongers in prostate cancer
Farooqı, A. A., & Bhatti, S. (2011) · Journal of Experimental and Integrative Medicine · doi:10.5455/jeim.060211.rw.001 · Cited by 2
Practical Polling for Prostate Cancer: AR-V7–based Treatment Selection
Lamb, A. D. G., Lawrence, M. G., & Sandhu, S. K. (2017) · European Urology · doi:10.1016/j.eururo.2016.12.028 · Cited by 2
Elucidating the roles of naturally occurring silent mutations in Polycystic Ovary Syndrome (PCOS)
Gümüşgül, M. D., Şahin, Ş., Turan, H., Karaca, B. T., & Kutlu, A. (2020) · Meta Gene · doi:10.1016/j.mgene.2020.100707 · Cited by 1
Androgen Receptor in Health and Disease
Hohl, A., & Marcelli, M. (2023) · Springer eBooks · doi:10.1007/978-3-031-31501-5_2 · Cited by 1
Comprehensive analysis of androgen receptor splice variant target gene expression in prostate cancer
Wüstmann, N., Reimann, J., Vieler, J., Humberg, V., Schlack, K., Bögemann, M., Schrader, A. J., & Bernemann, C. (2025) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2025.120062 · Cited by 1
Guo, J., Wu, K., Ma, Z., Guo, S., Wang, F., & Lu, L. (2026) · Frontiers in Oncology · doi:10.3389/fonc.2026.1837998 · Cited by 1
Wilson, E. M. (2015) · Springer eBooks · doi:10.1007/978-3-319-18729-7_8 · Cited by 1
Androgens and the androgen receptor (AR)
Moore, N. L. T., Centenera, M. M., Butler, L. M., Hickey, T. E., & Tilley, W. D. (2013) · Cambridge University Press eBooks · doi:10.1017/cbo9781139046947.033 · Cited by 1
The PI3K-mTOR Pathway in Prostate Cancer: Biological Significance and Therapeutic Opportunities
Wu, B. J., & Chung, L. W. K. (2016) · Cancer drug discovery and develogment/Cancer drug discovery and development · doi:10.1007/978-3-319-34211-5_9 · Cited by 1
Koo, K. M. (2019) · Springer theses · doi:10.1007/978-3-030-31000-4_1 · Cited by 1
Guzmán, J. C., Weigelt, K., Neumann, A., Tripal, P., Schmid, B., Winter, Z., Palmisano, R., Čulig, Z., Cronauer, M. V., Muschler, P., et al. (2024) · BMC Cancer · doi:10.20944/preprints202304.0280.v1
Current Pathophysiology, Treatment, and Future Perspective for Prostate Cancer
Dahiya, M., Yadav, M., Sharma, P., & Kumar, A. (2023) · Springer eBooks · doi:10.1007/978-981-99-2196-6_22-1 · Cited by 1
Current Pathophysiology, Treatment, and Future Perspective for Prostate Cancer
Dahiya, M., Yadav, M., Sharma, P., & Kumar, A. (2024) · Springer eBooks · doi:10.1007/978-981-99-6263-1_22 · Cited by 1
Molecular Biology in Diagnosis and Treatment of Prostate Cancer
Konaç, E., & Sözen, S. (2014) · Bulletin of Urooncology · doi:10.4274/uob.194 · Cited by 1
Androgenic modulation of AR-Vs
Hillebrand, A. C., Pizzolato, L. S., Branchini, G., & Brum, I. S. (2018) · Endocrine · doi:10.1007/s12020-018-1682-5 · Cited by 1
Yang, Y. C. (2016) · cIRcle (University of British Columbia) · doi:10.14288/1.0165748 · Cited by 1
Making Predictive Biomarkers Readily Available
Bjartell, A. S. (2016) · European Urology · doi:10.1016/j.eururo.2016.05.003 · Cited by 1
Zhao, X., Zhou, T.-R., Wang, Y., Bao, M., Ni, C., Ding, L., Sun, S., Dong, H., Li, J., & Liang, C. (2022) · Research Square · doi:10.21203/rs.3.rs-2190616/v1 · Cited by 1
Lee, S., Lai, K., Yeh, S., & Chang, C. (2011) · Springer eBooks · doi:10.1007/978-1-4614-1764-4_9 · Cited by 1
Jiang, Z. K. (2013) · eScholarship (California Digital Library)
Donkena, & Young, D. (2011) · InTech eBooks · doi:10.5772/24713
Plymate, S. R. (2012) · Defense Technical Information Center (DTIC) · doi:10.21236/ada566784
Molecular Indicators of Castration-resistant Prostate Cancer
Luo, J., & Diamond, B. (2013) · Defense Technical Information Center (DTIC) · doi:10.21236/ada598449
New Therapies in Hormone Relapsed Disease
Pezaro, C. J., Omlin, A. G., Bianchini, D., & Bono, J. S. D. (2014) · Prostate Cancer · doi:10.1002/9781118347379.ch14
Novel Therapeutic Settings in the Treatment of Castration- Resistant Prostate Cancer
Alvarez, M., Gómez, J. M. F., Jalon, A., Miguelez, E., & Valle, F. (2013) · InTech eBooks · doi:10.5772/52288
APPLICATION OF TARGETING NUCLEASES TO MODELING PROSTATE CANCER GENE REARRANGEMENTS.
Nyquist, M. D. (2014) · University of Minnesota Digital Conservancy (University of Minnesota)
Intermittierende Hormontherapie beim androgensensiblen Prostatakarzinom
Thelen, P., Ringert, R. H., Loertzer, H., & Strauß, A. (2012) · Der Urologe · doi:10.1007/s00120-012-2870-1
Molecular Mechanisms of Prostate Cancer Progression After Castration
Nelson, W. G., & Pienta, K. J. (2014) · Current clinical urology · doi:10.1007/978-1-4939-1176-9_3
Možnosti léčby kastračně refrakterního karcinomu prostaty, co nového k roku 2013
Matoušková, M., & Miroslav, H. (2013) · Česká urologie
Castrate‐resistant prostate cancer: the future of antiandrogens
Pchejetski, D., Alshaker, H. A., & Stebbing, J. (2014) · Trends in Urology & Men s Health · doi:10.1002/tre.371
Androgen receptor phosphorylation in prostate diseases
Willder, J. M. (2014) · Enlighten: Theses (The University of Glasgow) · doi:10.5525/gla.thesis.5797
Nair, P. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1107215108
Endocrine therapy for prostate cancer: review of the latest clinical evidence
Tsao, C., Seng, S. M., Oh, W. K., & Galsky, M. D. (2011) · Clinical Investigation · doi:10.4155/cli.11.28
Mutha, S. K. (2012) · University of Minnesota Digital Conservancy (University of Minnesota)
Mechanisms behind growth of castration-resistant prostate cancer bone metastases
Jernberg, E. (2013) · KTH Publication Database DiVA (KTH Royal Institute of Technology)
The androgen receptor and clinical challenges
Payne, H. A., Sedelaar, J. P. M., & Jones, R. J. (2014) · Trends in Urology & Men s Health · doi:10.1002/tre.390
Overexpression of Androgen Receptor in Prostate Cancer
Urbanucci, A. (2012) · Tampere University Institutional Repository (Tampere University)
Tavakoli, I. (2013) · cIRcle (University of British Columbia) · doi:10.14288/1.0072850
Alekseev, B. Y., & Андрианов, А. Н. (2014) · Oncourology (Russian Society of Oncourologists) · doi:10.17650/1726-9776-2013-9-1-68-73
Androgeenireseptorin tumatranslokaatio, FOXA1-vuorovaikutus ja liikkuvuus ihmisen soluissa
Rahkama, V. (2012) · Jyväskylä University Digital Archive (University of Jyväskylä)
Hormone-Based Therapies for Castration-Resistant Prostate Cancer
Mostaghel, E. A., & Nelson, P. S. (2012) · Springer eBooks · doi:10.1007/978-1-4471-2864-9_74
Characterizing Molecular Modifiers of Pathogenesis in Spinobulbar Muscular Atrophy.
Chua, C., & Portnof, J. E. (2015) · Deep Blue (University of Michigan)
Metastatic Castrate-resistant Prostate Cancer: When and How to Treat?
Taylor, D., & Machiels, J. (2013) · The Journal of OncoPathology · doi:10.13032/tjop.2052-5931.100052
Obinata, D. (2014) · World Journal of Clinical Urology · doi:10.5410/wjcu.v3.i3.264
Androgen Receptor Signaling in Castration Resistant Prostate Cancer
Zhao, Y., Tindall, D. J., & Huang, H. (2016) · Springer eBooks · doi:10.1007/978-3-319-31341-2_3
Li, Y., & Dehm, S. M. (2016) · Methods in molecular biology · doi:10.1007/978-1-4939-3724-0_11
O uso de microRNA para tratamento do câncer de próstata: estudos in vitro e in vivo
Iscaife, A. (2016) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/t.5.2016.tde-22082016-104926
Wong, N. (2016) · MacSphere (McMaster University) · doi:10.71548/15872
A brief overview of androgen receptor: Its structure, functions and role in health and disease
Nikhil, K., Sharan, S., & Roy, P. (2013) · Journal of Endocrinology & Reproduction · doi:10.18519/jer/2013/v17/75783
Androgen receptor-mediated growth suppression and apoptosis of human prostate epithelial cells
Chen, C. (2016) · Illinois Digital Environment for Access to Learning and Scholarship (University of Illinois at Urbana-Champaign)
Obinata, D., & Takahashi, S. (2014) · Journal of Nihon University Medical Association · doi:10.4264/numa.73.134
Pereira, B. J. (2017) · Journal of Urology and Nephrology Open Access · doi:10.15226/2473-6430/3/3/00132
Bypassing androgen pathway dependence in advanced prostate cancer.
Bluemn, E. G. (2012) · ResearchWorks at the University of Washington (University of Washington)
Castration-Resistant Prostate Cancer
Davies, A., Bishop, J. L., & Zoubeidi, A. (2017) · Molecular pathology library · doi:10.1007/978-3-319-64096-9_18
AR Splice Variant in Prostate Cancer
Yamashita, S., & Arai, Y. (2018) · Springer eBooks · doi:10.1007/978-981-10-7013-6_29
Chromatin reprogramming as adaptation mechanism in advanced prostate cancer
Urbanucci, A. (2018) · European Urology Supplements · doi:10.1016/s1569-9056(18)32987-7
Discovery Of Piperlongumine Derivatives As Anti-Leukemic And Anti-Prostate Cancer Agents
Liao, Y. (2018) · Human Biology
Saha, B. B., Thu, K., & Wijayanta, A. T. (2018) · Evergreen · doi:10.5109/1957499
Targeted Therapies for Bone Metastases
Santini, D., Spoto, C., Longo, V., Iuliani, M., Zoccoli, A., Intagliata, S., Pantano, F., & Silvestris, F. (2015) · Current clinical pathology · doi:10.1007/978-1-4939-2047-1_18
Organ system effects: endocrine toxicology
Denslow, N. D., & Martyniuk, C. J. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-813602-7.00017-x
Liao, J.-G., & Pan, W. (2020) · International Journal of Sciences · doi:10.18483/ijsci.2303
Development of novel androgen receptor inhibitors to overcome castrate-resistant prostate cancer
Saraç, H., Cherkasov, A. R., & Lack, N. A. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-821310-0.00007-3
Bataller, J. C. (1983) · Papers de joventut: informatiu
Metadata
- Authors
- Watson, P. A., Chen, Y. F., Balbas, M. D., Wongvipat, J., Socci, N. D., Viale, A., Kim, K., & Sawyers, C. L.
- Affiliations
- Memorial Sloan Kettering Cancer Center (US)
- Human Oncology and Pathogenesis Program,
- Bioinformatics Core,
- University of California, Los Angeles (US)
- Howard Hughes Medical Institute (US)
- Corresponding author
- Sawyers, Charles L.
- Venue
- Proceedings of the National Academy of Sciences
- Publisher
- National Academy of Sciences
- Published
- 2010-09-07
- Volume
- 107
- Issue
- 39
- Pages
- 16759-16765
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- PMC
- PMC2947883
- OpenAlex
- W2083926838
- Cited by
- 639
- References
- 27
- Citations by year
- 2026: 8 · 2025: 19 · 2024: 22 · 2023: 33 · 2022: 25 · 2021: 26 · 2020: 43 · 2019: 33 · 2018: 36 · 2017: 43 · 2016: 63 · 2015: 48 · 2014: 64 · 2013: 65 · 2012: 53
- FWCI
- 46.52
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Proceedings of the National Academy of Sciences (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Howard Hughes Medical Institute
- Prostate Cancer Foundation
- University of Washington
- National Cancer Institute
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Prostate Cancer Treatment and Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Chromatin Remodeling and Cancer
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Hormonal and reproductive studies
- Keywords
- androgen receptor splice variants, castration-resistant prostate cancer, AR-V7, ligand-independent receptor activation, full-length androgen receptor, androgen withdrawal, antiandrogen resistance, enzalutamide, anchorage-independent growth, siRNA knockdown, prostate cancer cell lines, androgen receptor isoforms
- MeSH terms
- Amino Acid Sequence, Androgens, Animals, Castration, Disease Models, Animal, Exons, Humans, Male, Molecular Sequence Data, Prostatic Neoplasms, Receptors, Androgen, RNA, Messenger, Gene Expression Regulation, Neoplastic, Alternative Splicing, Protein Structure, Tertiary, Sequence Analysis, Protein, Cell Line, Tumor, Mice, Androgen Receptor Antagonists
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
